Literature DB >> 32092046

Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.

Pinar Hamurcu Varol1,2, Eda Kaya3, Emel Alphan1, Yusuf Yilmaz3,4.   

Abstract

BACKGROUND/AIM: Although weight loss is recommended for the treatment of nonalcoholic fatty liver disease (NAFLD) in overweight and obese individuals, this treatment modality remains questionable in lean individuals. In this study, we investigated the effects of medical nutrition therapy (MNT) and intensive lifestyle interventions (ILIs) for NAFLD in lean versus obese patients.
METHODS: In total, 35 patients (14 lean and 21 obese) were included in the study. All patients underwent transient elastography examinations, and controlled attenuation parameter (CAP) of >238 dB/m was indicative of hepatic steatosis. After 8 weeks of dietitian follow-up with MNT and ILI, the patients were compared with the baseline.
RESULTS: Significant weight loss was recorded in both lean (5.4%) and obese patients (5.7%) with NAFLD. The mean BMI decreased from 23.9 (20.5-24.8) to 22.4 (19.5-24.2) kg/m (P = 0.001) in lean patients and from 34.0 (30.0-42.0) to 31.6 (26.9-42.5) kg/m (P < 0.001) in obese patients. The alanine aminotransferase level significantly decreased from 56 (15-163) to 28 (13-98) U/L (P = 0.010) in lean patients and from 27 (13-81) to 22 (13-46) U/L (P = 0.018) in obese patients. The median CAP decreased from 299 (246-360) to 236 (169-318) dB/m (P = 0.002) in lean patients and from 325 (258-400) to 253 (202-383) dB/m (P < 0.001) in obese patients. Moreover, remission of hepatic steatosis was detected in eight lean patients (57.1%) and eight obese patients (38.1%).
CONCLUSION: These results indicate that 5% body weight loss in effective in both obese and lean patients resulting in a similar NAFLD remission.

Entities:  

Mesh:

Year:  2020        PMID: 32092046     DOI: 10.1097/MEG.0000000000001656

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  14 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

2.  Direct access lifestyle training improves liver biochemistry and causes weight loss but uptake is suboptimal in patients with non-alcoholic fatty liver disease.

Authors:  Imran Patanwala; Lili Emese Molnar; Katherine Akerboom; Katie Elizabeth Lane
Journal:  Frontline Gastroenterol       Date:  2020-11-20

Review 3.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

4.  Value of Visceral Fat Area and Resting Energy Expenditure in Assessment of Metabolic Characteristics in Obese and Lean Nonalcoholic Fatty Liver Disease.

Authors:  Qing Ye; Junqing Yan; Hui-Juan Xiao; Tao Han
Journal:  Turk J Gastroenterol       Date:  2021-02       Impact factor: 1.852

Review 5.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

6.  Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.

Authors:  Lampros Chrysavgis; Eleftheria Ztriva; Adonis Protopapas; Konstantinos Tziomalos; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

Review 7.  Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date.

Authors:  Małgorzata Moszak; Monika Szulińska; Marta Walczak-Gałęzewska; Paweł Bogdański
Journal:  Int J Environ Res Public Health       Date:  2021-02-08       Impact factor: 3.390

8.  Calcium to magnesium intake ratio and non-alcoholic fatty liver disease development: a case-control study.

Authors:  Hadi Emamat; Hamid Ghalandari; Ali Saneei Totmaj; Hadith Tangestani; Azita Hekmatdoost
Journal:  BMC Endocr Disord       Date:  2021-03-18       Impact factor: 2.763

9.  Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.

Authors:  Ayşegül Avcu; Eda Kaya; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-05       Impact factor: 1.852

Review 10.  Lean NAFLD: an underrecognized and challenging disorder in medicine.

Authors:  Sheila Maier; Amanda Wieland; Melanie Cree-Green; Kristen Nadeau; Shelby Sullivan; Miguel A Lanaspa; Richard J Johnson; Thomas Jensen
Journal:  Rev Endocr Metab Disord       Date:  2021-01-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.